CMS Open Payments · Program Year 2024
Lumos Diagnostics, Inc.
Lumos Diagnostics, Inc. reported $18,539.56 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 3 transactions.
- $18.5K
- All-tracks total
- 3
- Transactions
- 2
- Recipients
- #1545
- of 1,925 companies
Lumos Diagnostics, Inc. reported $18,539.56 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1545 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,939.56, averaging $9.3K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer lumos-diagnostics-inc Lumos Diagnostics, Inc.
$18.5K · #1545/1,925 · 0.0% industry · PY2024
- TOT $18.5K
- RANK #1545
- SHARE 0.0%
- TXN 3
- RCP 2
- CAT 2
- GEN $3.9K
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: American Surgical Company, LLC ($18.8K)
Lumos Diagnostics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Lumos Diagnostics, Inc.
Rank #1545 of 1,925 companies in CMS Open Payments for 2024 belongs to Lumos Diagnostics, Inc., which reported $18,539.56 across 3 transactions to 2 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $6.2K per transaction and $9.3K per recipient.
"Compensation for Faculty or Speaker (Medical Education)" leads the 2-category general-payment breakdown below at $3.0K (76.2% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Compensation for Faculty or Speaker (Medical Education)" leads Lumos Diagnostics, Inc.'s 2-category general-payment breakdown at $3.0K, 76.2% of the reported total.
How Lumos Diagnostics, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Faculty or Speaker (Medical Education) | $3.0K | 1 | 76.2% |
| Travel and Lodging | $939.56 | 1 | 23.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,939.56 (100.0%) of $3,939.56 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Lumos Diagnostics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Nathan Shapiro
$3,939.56 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Lumos Diagnostics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Lumos Diagnostics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Lumos Diagnostics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Bayer Puerto Rico Inc.
Ostial Corporation
Alvogen Inc
Novabone Products
Ferring SA de CV
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.